際際滷shows by User: JackWestMD / http://www.slideshare.net/images/logo.gif 際際滷shows by User: JackWestMD / Tue, 24 May 2016 18:04:41 GMT 際際滷Share feed for 際際滷shows by User: JackWestMD Top 10 asco 2016 abstracts for lung cancer (and mesothelioma) /slideshow/top-10-asco-2016-abstracts-for-lung-cancer-and-mesothelioma/62355153 top10asco2016abstractsforlungcancer524-160524180441
My recommended top 10 most relevant abstracts being presented on lung cancer or mesothelioma at the ASCO 2016 annual meeting.]]>
My recommended top 10 most relevant abstracts being presented on lung cancer or mesothelioma at the ASCO 2016 annual meeting.]]> Tue, 24 May 2016 18:04:41 GMT /slideshow/top-10-asco-2016-abstracts-for-lung-cancer-and-mesothelioma/62355153 JackWestMD@slideshare.net(JackWestMD) Top 10 asco 2016 abstracts for lung cancer (and mesothelioma) JackWestMD My recommended top 10 most relevant abstracts being presented on lung cancer or mesothelioma at the ASCO 2016 annual meeting. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/top10asco2016abstractsforlungcancer524-160524180441-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> My recommended top 10 most relevant abstracts being presented on lung cancer or mesothelioma at the ASCO 2016 annual meeting.
Top 10 asco 2016 abstracts for lung cancer (and mesothelioma) from H. Jack West
]]> 17596 9 https://cdn.slidesharecdn.com/ss_thumbnails/top10asco2016abstractsforlungcancer524-160524180441-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 3 Key Steps for Personalized Cancer Medicine /slideshow/precision-medicine-beyond-the-hype/44235950 precisionmedicinebeyondthehype-150203183917-conversion-gate02
The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype? Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn't just delivering false hope for most patients.]]>
The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype? Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn't just delivering false hope for most patients.]]> Tue, 03 Feb 2015 18:39:17 GMT /slideshow/precision-medicine-beyond-the-hype/44235950 JackWestMD@slideshare.net(JackWestMD) Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine JackWestMD The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype? Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn't just delivering false hope for most patients. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/precisionmedicinebeyondthehype-150203183917-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The concept of personalized or precision medicine is hot enough that President Obama is launching initiatives for it, but how close is it to moving beyond hype? Here are 3 key steps we need to attain to know that personalized medicine, particularly in the world of cancer care, isn&#39;t just delivering false hope for most patients.
Moving Beyond the Hype: 3 Key Steps for Personalized Cancer Medicine from H. Jack West
]]> 12061 21 https://cdn.slidesharecdn.com/ss_thumbnails/precisionmedicinebeyondthehype-150203183917-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Top 5 highlights in lung cancer, 2014 /slideshow/top-5-highlights-in-lung-cancer-2014/42922413 top5highlightsinlungcancer2014-141221225351-conversion-gate02
My list of the top 5 developments in lung cancer in 2014.]]>
My list of the top 5 developments in lung cancer in 2014.]]> Sun, 21 Dec 2014 22:53:51 GMT /slideshow/top-5-highlights-in-lung-cancer-2014/42922413 JackWestMD@slideshare.net(JackWestMD) Top 5 highlights in lung cancer, 2014 JackWestMD My list of the top 5 developments in lung cancer in 2014. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/top5highlightsinlungcancer2014-141221225351-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> My list of the top 5 developments in lung cancer in 2014.
Top 5 highlights in lung cancer, 2014 from H. Jack West
]]> 3401 4 https://cdn.slidesharecdn.com/ss_thumbnails/top5highlightsinlungcancer2014-141221225351-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Best of ASCO Metastatic Non-Small Cell Lung Cancer /slideshow/best-of-asco-metastatic-nonsmall-cell-lung-cancer/38302723 westbestofascofinal-140824120245-phpapp02
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.]]>
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.]]> Sun, 24 Aug 2014 12:02:45 GMT /slideshow/best-of-asco-metastatic-nonsmall-cell-lung-cancer/38302723 JackWestMD@slideshare.net(JackWestMD) Best of ASCO Metastatic Non-Small Cell Lung Cancer JackWestMD Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westbestofascofinal-140824120245-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West&#39;s presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.
Best of ASCO Metastatic Non-Small Cell Lung Cancer from H. Jack West
]]> 7551 12 https://cdn.slidesharecdn.com/ss_thumbnails/westbestofascofinal-140824120245-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 10 Key ASCO 2014 Presentations in Lung Cancer /slideshow/10-key-asco-2014-presentations-in-lung-cancer/34824071 10keyasco2014presentationsinlungcancer-140518113019-phpapp01
Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.]]>
Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.]]> Sun, 18 May 2014 11:30:19 GMT /slideshow/10-key-asco-2014-presentations-in-lung-cancer/34824071 JackWestMD@slideshare.net(JackWestMD) 10 Key ASCO 2014 Presentations in Lung Cancer JackWestMD Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/10keyasco2014presentationsinlungcancer-140518113019-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West offers a list of 10 of the most important, timely abstract presentations in lung cancer, both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), at the annual ASCO 2014 conference.
10 Key ASCO 2014 Presentations in Lung Cancer from H. Jack West
]]> 22900 20 https://cdn.slidesharecdn.com/ss_thumbnails/10keyasco2014presentationsinlungcancer-140518113019-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung Cancer /JackWestMD/transitioning-from-months-to-years-in-adv-nsclc-final transitioningfrommonthstoyearsinadvnsclcfinal-140510122529-phpapp02
Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation.]]>
Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation.]]> Sat, 10 May 2014 12:25:29 GMT /JackWestMD/transitioning-from-months-to-years-in-adv-nsclc-final JackWestMD@slideshare.net(JackWestMD) Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung Cancer JackWestMD Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/transitioningfrommonthstoyearsinadvnsclcfinal-140510122529-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West reviews the evolution of new treatment options for advanced NSCLC that have steadily improved survival. This progress has been incremental but now means that an ever-growing proportion of patients with advanced NSCLC have a realistic promise of potentially living several years after their diagnosis and the start of treatment. Note that this presentation does not address advances in immunotherapy, which were covered in a separate talk at the same conference at which Dr. West delivered this presentation.
Transitioning Survival from Months to Years in Advanced Non-Small Cell Lung Cancer from H. Jack West
]]> 7862 8 https://cdn.slidesharecdn.com/ss_thumbnails/transitioningfrommonthstoyearsinadvnsclcfinal-140510122529-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 What is the value of maintenance therapy in advanced NSCLC, and who should get it? /slideshow/maintenance-therapy-primer/33454420 maintenancetherapyprimer-140412192327-phpapp02
Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.]]>
Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.]]> Sat, 12 Apr 2014 19:23:27 GMT /slideshow/maintenance-therapy-primer/33454420 JackWestMD@slideshare.net(JackWestMD) What is the value of maintenance therapy in advanced NSCLC, and who should get it? JackWestMD Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/maintenancetherapyprimer-140412192327-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West reviews the rationale for maintenance therapy in advanced NSCLC, what the evidence shows about its value, the limitations, and thoughts on which patients should or should not pursue it.
What is the value of maintenance therapy in advanced NSCLC, and who should get it? from H. Jack West
]]> 6677 5 https://cdn.slidesharecdn.com/ss_thumbnails/maintenancetherapyprimer-140412192327-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 50 Shades of Cancer Progression: The Continuum of Progression & How We Decide When to Change Treatment /slideshow/50-shades-of-cancer-progression/33127757 50shadesofcancerprogression-140404074741-phpapp01
Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much?]]>
Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much?]]> Fri, 04 Apr 2014 07:47:41 GMT /slideshow/50-shades-of-cancer-progression/33127757 JackWestMD@slideshare.net(JackWestMD) 50 Shades of Cancer Progression: The Continuum of Progression & How We Decide When to Change Treatment JackWestMD Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much? <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/50shadesofcancerprogression-140404074741-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West reviews the importance of assessing the degree of progression when interpreting whether to change treatment of a cancer. It is important to ask not only whether a cancer has progressed, but HOW it has done so, and how much?
50 Shades of Cancer Progression: The Continuum of Progression & How We Decide When to Change Treatment from H. Jack West
]]> 4614 5 https://cdn.slidesharecdn.com/ss_thumbnails/50shadesofcancerprogression-140404074741-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Inherited T790M EGFR Mutation and Lung Cancer Risk /JackWestMD/inherited-t790-m-egfr-mutation inheritedt790megfrmutation-140330222029-phpapp02
Dr. Jack West reviews evidence on an inherited gene that leads to a 31% risk of developing lung cancer among those who inherit it. ]]>
Dr. Jack West reviews evidence on an inherited gene that leads to a 31% risk of developing lung cancer among those who inherit it. ]]> Sun, 30 Mar 2014 22:20:29 GMT /JackWestMD/inherited-t790-m-egfr-mutation JackWestMD@slideshare.net(JackWestMD) Inherited T790M EGFR Mutation and Lung Cancer Risk JackWestMD Dr. Jack West reviews evidence on an inherited gene that leads to a 31% risk of developing lung cancer among those who inherit it. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/inheritedt790megfrmutation-140330222029-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Jack West reviews evidence on an inherited gene that leads to a 31% risk of developing lung cancer among those who inherit it.
Inherited T790M EGFR Mutation and Lung Cancer Risk from H. Jack West
]]> 5049 12 https://cdn.slidesharecdn.com/ss_thumbnails/inheritedt790megfrmutation-140330222029-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Key Clinical Implications of how a Cancer Evolves /slideshow/clinical-implications-of-how-a-cancer-evolves-32647741/32647741 clinicalimplicationsofhowacancerevolves-140323215210-phpapp01
Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations.]]>
Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations.]]> Sun, 23 Mar 2014 21:52:10 GMT /slideshow/clinical-implications-of-how-a-cancer-evolves-32647741/32647741 JackWestMD@slideshare.net(JackWestMD) Key Clinical Implications of how a Cancer Evolves JackWestMD Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/clinicalimplicationsofhowacancerevolves-140323215210-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Cancer adapts and evolves over time and under the selective pressure of systemic treatment, becoming increasingly resistant over time. This brief slidedoc fo summarizes key points in how cancer adaptation leads to resistance and changes our treatment recommendations.
Key Clinical Implications of how a Cancer Evolves from H. Jack West
]]> 3827 6 https://cdn.slidesharecdn.com/ss_thumbnails/clinicalimplicationsofhowacancerevolves-140323215210-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Treating Invisible Disease: How the Probability of Disease We Can't See Changes Our Treatment Strategy in Lung Cancer /slideshow/treating-invisible-disease-grace/32381254 treatinginvisiblediseasegrace-140316210525-phpapp02
A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can't when we shape our treatment recommendations in lung cancer and many other cancers.]]>
A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can't when we shape our treatment recommendations in lung cancer and many other cancers.]]> Sun, 16 Mar 2014 21:05:25 GMT /slideshow/treating-invisible-disease-grace/32381254 JackWestMD@slideshare.net(JackWestMD) Treating Invisible Disease: How the Probability of Disease We Can't See Changes Our Treatment Strategy in Lung Cancer JackWestMD A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can't when we shape our treatment recommendations in lung cancer and many other cancers. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/treatinginvisiblediseasegrace-140316210525-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A brief slidedoc that reviews why we focus on both the cancer we can see and the potential cancer we can&#39;t when we shape our treatment recommendations in lung cancer and many other cancers.
Treating Invisible Disease: How the Probability of Disease We Can't See Changes Our Treatment Strategy in Lung Cancer from H. Jack West
]]> 4111 13 https://cdn.slidesharecdn.com/ss_thumbnails/treatinginvisiblediseasegrace-140316210525-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Changes Afoot: Changing Relationships between Engaged Patients and Docs in Cancer Care /JackWestMD/changes-afoot-changing-relationships-between-engaged-patients-and-docs-in-cancer-care patientanddocengagementonlinewest-140306135905-phpapp02
Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care.]]>
Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care.]]> Thu, 06 Mar 2014 13:59:04 GMT /JackWestMD/changes-afoot-changing-relationships-between-engaged-patients-and-docs-in-cancer-care JackWestMD@slideshare.net(JackWestMD) Changes Afoot: Changing Relationships between Engaged Patients and Docs in Cancer Care JackWestMD Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/patientanddocengagementonlinewest-140306135905-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Discussion of how online patient communities and social media are changing relationships between engaged patients and oncologists, improving quality of cancer care.
Changes Afoot: Changing Relationships between Engaged Patients and Docs in Cancer Care from H. Jack West
]]> 473 2 https://cdn.slidesharecdn.com/ss_thumbnails/patientanddocengagementonlinewest-140306135905-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Patient and doc engagement online west /slideshow/patient-and-doc-engagement-online-west-32004862/32004862 patientanddocengagementonlinewest-140306135757-phpapp01
]]>
]]> Thu, 06 Mar 2014 13:57:57 GMT /slideshow/patient-and-doc-engagement-online-west-32004862/32004862 JackWestMD@slideshare.net(JackWestMD) Patient and doc engagement online west JackWestMD <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/patientanddocengagementonlinewest-140306135757-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Patient and doc engagement online west from H. Jack West
]]> 421 4 https://cdn.slidesharecdn.com/ss_thumbnails/patientanddocengagementonlinewest-140306135757-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix /slideshow/west-immunotherapy-vaccines-for-lung-cancer-magea3-stimuvax-and-lucanix/31490570 westvaccinesfornsclcmage-a3stimuvaxlucanix-140221125550-phpapp02
Update of results and current clinical trials of vaccines for lung cancer, including MAGE-A3, Stimuvax, and Lucanix for stage I-III non-small cell lung cancer. @JackWestMD, @CancerGRACE cancerGRACE.org]]>
Update of results and current clinical trials of vaccines for lung cancer, including MAGE-A3, Stimuvax, and Lucanix for stage I-III non-small cell lung cancer. @JackWestMD, @CancerGRACE cancerGRACE.org]]> Fri, 21 Feb 2014 12:55:50 GMT /slideshow/west-immunotherapy-vaccines-for-lung-cancer-magea3-stimuvax-and-lucanix/31490570 JackWestMD@slideshare.net(JackWestMD) West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix JackWestMD Update of results and current clinical trials of vaccines for lung cancer, including MAGE-A3, Stimuvax, and Lucanix for stage I-III non-small cell lung cancer. @JackWestMD, @CancerGRACE cancerGRACE.org <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westvaccinesfornsclcmage-a3stimuvaxlucanix-140221125550-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Update of results and current clinical trials of vaccines for lung cancer, including MAGE-A3, Stimuvax, and Lucanix for stage I-III non-small cell lung cancer. @JackWestMD, @CancerGRACE cancerGRACE.org
West Immunotherapy, Vaccines for Lung Cancer Mage-A3, Stimuvax, and Lucanix from H. Jack West
]]> 2124 7 https://cdn.slidesharecdn.com/ss_thumbnails/westvaccinesfornsclcmage-a3stimuvaxlucanix-140221125550-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer: New Ideas, New Agents /slideshow/acquired-resistance-to-targeted-therapy-in-lung-cancer-new-ideas-new-agents/31317245 westacquiredresistancefeb2014-140217195355-phpapp01
This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials.]]>
This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials.]]> Mon, 17 Feb 2014 19:53:55 GMT /slideshow/acquired-resistance-to-targeted-therapy-in-lung-cancer-new-ideas-new-agents/31317245 JackWestMD@slideshare.net(JackWestMD) Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer: New Ideas, New Agents JackWestMD This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westacquiredresistancefeb2014-140217195355-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This is a presentation I did for a meeting on new general management of acquired resistance in 2014, including the concept of local therapy for limited progression, and new treatment approaches and new agents for this setting. It features discussion of several of the most important trials.
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer: New Ideas, New Agents from H. Jack West
]]> 8833 24 https://cdn.slidesharecdn.com/ss_thumbnails/westacquiredresistancefeb2014-140217195355-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 West asco clin mgmt acquired resistance tk is /slideshow/west-asco-clin-mgmt-acquired-resistance-tk-is/22632675 westascoclinmgmtacquiredresistancetkis-130607204626-phpapp01
]]>
]]> Fri, 07 Jun 2013 20:46:26 GMT /slideshow/west-asco-clin-mgmt-acquired-resistance-tk-is/22632675 JackWestMD@slideshare.net(JackWestMD) West asco clin mgmt acquired resistance tk is JackWestMD <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westascoclinmgmtacquiredresistancetkis-130607204626-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
West asco clin mgmt acquired resistance tk is from H. Jack West
]]> 461 4 https://cdn.slidesharecdn.com/ss_thumbnails/westascoclinmgmtacquiredresistancetkis-130607204626-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC) /slideshow/acquired-resistance-to-egfr-tkis-in-lung-cancer-nsclc/12641734 acquiredresistancetoegfrtkis-120422133455-phpapp01
Discussion of mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer after an initial good response. ]]>
Discussion of mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer after an initial good response. ]]> Sun, 22 Apr 2012 13:34:54 GMT /slideshow/acquired-resistance-to-egfr-tkis-in-lung-cancer-nsclc/12641734 JackWestMD@slideshare.net(JackWestMD) Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC) JackWestMD Discussion of mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer after an initial good response. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/acquiredresistancetoegfrtkis-120422133455-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Discussion of mechanisms of resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer after an initial good response.
Acquired resistance to EGFR TKIs in Lung Cancer (NSCLC) from H. Jack West
]]> 8149 22 https://cdn.slidesharecdn.com/ss_thumbnails/acquiredresistancetoegfrtkis-120422133455-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 West egfr mutation acquired resistance /JackWestMD/west-egfr-mutation-acquired-resistance westegfrmutationacquiredresistance-111022152624-phpapp02
Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response.]]>
Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response.]]> Sat, 22 Oct 2011 15:26:24 GMT /JackWestMD/west-egfr-mutation-acquired-resistance JackWestMD@slideshare.net(JackWestMD) West egfr mutation acquired resistance JackWestMD Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westegfrmutationacquiredresistance-111022152624-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Review by Dr. H. Jack West of current understanding of mechanisms behind and emerging treatment options for patients with advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors after a good initial response.
West egfr mutation acquired resistance from H. Jack West
]]> 1257 6 https://cdn.slidesharecdn.com/ss_thumbnails/westegfrmutationacquiredresistance-111022152624-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 West xcenda molec testing sf oct 2011 revised final /slideshow/west-xcenda-molec-testing-sf-oct-2011-revised-final/9832430 westxcendamolectestingsfoct2011revisedfinal-111022114425-phpapp01
]]>
]]> Sat, 22 Oct 2011 11:44:23 GMT /slideshow/west-xcenda-molec-testing-sf-oct-2011-revised-final/9832430 JackWestMD@slideshare.net(JackWestMD) West xcenda molec testing sf oct 2011 revised final JackWestMD <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/westxcendamolectestingsfoct2011revisedfinal-111022114425-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
West xcenda molec testing sf oct 2011 revised final from H. Jack West
]]> 665 6 https://cdn.slidesharecdn.com/ss_thumbnails/westxcendamolectestingsfoct2011revisedfinal-111022114425-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Dr. Jack West Oncology 2.0, to WA AG's Office /slideshow/dr-jack-west-oncology-20-to-wa-ags-office/9720895 jackwesttowaagoffice-111016101219-phpapp01
Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General's office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic.]]>
Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General's office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic.]]> Sun, 16 Oct 2011 10:12:16 GMT /slideshow/dr-jack-west-oncology-20-to-wa-ags-office/9720895 JackWestMD@slideshare.net(JackWestMD) Dr. Jack West Oncology 2.0, to WA AG's Office JackWestMD Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General's office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/jackwesttowaagoffice-111016101219-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. H. Jack West, medical oncologist and Founder/CEO of Global Resource for Advancing Cancer Education (GRACE, www.CancerGRACE.org), spoke to WA state Attorney General&#39;s office about the changing landscape of cancer care and how the internet and specifically online patient communities and education will become disruptive in changing the patient/physician dynamic.
Dr. Jack West Oncology 2.0, to WA AG's Office from H. Jack West
]]> 584 3 https://cdn.slidesharecdn.com/ss_thumbnails/jackwesttowaagoffice-111016101219-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-JackWestMD-48x48.jpg?cb=1615143056 Medical Oncologist with a clinical focus and a strong background in lab-based research. My current interest is in clinical practice with a subspecialized focus on thoracic oncology and GU oncology, as well as translational research in these clinical populations. I have run a wide range of clinical trials for my institution, for clinical trials consortia, and at the national level through the cooperative group network (Southwest Oncology Group). I also am very interested in educational programs for both physicians and the general public and serve as President and CEO of GRACE, the Global Resource for Advancing Cancer Education. http://www.cancergrace.org/lung https://cdn.slidesharecdn.com/ss_thumbnails/top10asco2016abstractsforlungcancer524-160524180441-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/top-10-asco-2016-abstracts-for-lung-cancer-and-mesothelioma/62355153 Top 10 asco 2016 abstr... https://cdn.slidesharecdn.com/ss_thumbnails/precisionmedicinebeyondthehype-150203183917-conversion-gate02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/precision-medicine-beyond-the-hype/44235950 Moving Beyond the Hype... https://cdn.slidesharecdn.com/ss_thumbnails/top5highlightsinlungcancer2014-141221225351-conversion-gate02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/top-5-highlights-in-lung-cancer-2014/42922413 Top 5 highlights in lu...